INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 273 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2023. The put-call ratio across all filers is 0.28 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $792,654 | -17.7% | 15,217 | 0.0% | 2.55% | -16.4% |
Q2 2023 | $963,540 | +10.3% | 15,217 | -5.7% | 3.05% | +25.7% |
Q1 2023 | $873,548 | -11.2% | 16,132 | -13.2% | 2.42% | -24.7% |
Q4 2022 | $983,889 | -21.1% | 18,592 | -30.6% | 3.22% | -25.0% |
Q3 2022 | $1,247,000 | -42.0% | 26,792 | -28.9% | 4.29% | -53.6% |
Q2 2022 | $2,151,000 | -22.8% | 37,692 | -17.2% | 9.25% | +43.7% |
Q1 2022 | $2,786,000 | -25.8% | 45,533 | -36.5% | 6.44% | +112.7% |
Q4 2021 | $3,755,000 | – | 71,742 | – | 3.03% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |